Broad-acting antivirals: the pursuit of pan-viral therapeutics in the era of pandemics
Journal of Virology · 2026
DOI: 10.1128/jvi.00077-26 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Virology, 2026. Verfasst von Ekaterina Bayurova und 4 weiteren Autor:innen. Beteiligte Einrichtung: Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliom…. Hauptthemen laut MEDLINE: Antiviral Agents, SARS-CoV-2, COVID-19 Drug Treatment. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
The ever-present threat of new viral epidemics makes the scientific community relentlessly work on the development of universal methods of antiviral therapy. The development of broad-spectrum antivirals (BSAs) focuses either on substances acting directly on viral proteins (direct-acting antivirals [DAA]) or on substances directed at the cell’s own proteins (host-targeting antivirals [HTA]). Decades of development have led to the market entry of a number of DAAs with a wide range of antiviral activities; however, their clinical approval has been obtained for individual infections. HTAs have a number of advantages over DAAs, such as a wider range of antiviral activities and a high genetic barrier to viral resistance, which is undoubtedly important when preparing for a battle with an unknown pathogen. The COVID-19 pandemic has allowed for multiple clinical trials for repurposed HTAs, previously licensed for the treatment of other diseases, including cancer. Despite the enormous work done, the arsenal of BSAs capable of protecting against future pandemics caused by pathogen X is very limited. In this review, we described data on the most studied DAAs and HTAs, effective against at least two unrelated viral pathogens, focusing on those that have been studied in late preclinical and clinical trials. In the end, we highlighted alternative new approaches such as CRISPR-Cas therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Moscow, Russia.
- Department of Biotechnology, Sechenov University, Moscow, Russia.
- Center for Precision Genetic Technologies for Medicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
- Laboratory of Genetic Technologies in Drug Development, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, Sechenov University, Moscow, Russia.
- Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia.
- Laboratory of Experimental Therapy of Infectious Diseases, Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, Sechenov University, Moscow, Russia.
ORCID-Profile: Ekaterina Bayurova, Dmitry Kostyushev, Andrey Tikhonov, Ilya Gordeychuk
Förderung
- Russian Science Foundation
Zitieren
APA
Bayurova, E., Kostyushev, D., Tikhonov, A., Chulanov, V., & Gordeychuk, I. (2026). Broad-acting antivirals: the pursuit of pan-viral therapeutics in the era of pandemics. Journal of Virology. https://doi.org/10.1128/jvi.00077-26
Vancouver
Bayurova E, Kostyushev D, Tikhonov A, Chulanov V, Gordeychuk I. Broad-acting antivirals: the pursuit of pan-viral therapeutics in the era of pandemics. Journal of Virology. 2026. doi:10.1128/jvi.00077-26
BibTeX
@article{Bayurova2026,
author = {Bayurova, Ekaterina and Kostyushev, Dmitry and Tikhonov, Andrey and Chulanov, Vladimir and Gordeychuk, Ilya},
title = {Broad-acting antivirals: the pursuit of pan-viral therapeutics in the era of pandemics},
journal = {Journal of Virology},
year = {2026},
doi = {10.1128/jvi.00077-26}
}
EUVIMED